logo
Markets Reverse Course as August Begins - Middle East Business News and Information

Markets Reverse Course as August Begins - Middle East Business News and Information

Mid East Infoa day ago
By Daniela Sabin Hathorn, senior market analyst at Capital.com
The month of August has opened with a notable reversal in global financial markets. Echoing similar moves seen in 2024, investor sentiment has turned swiftly in response to disappointing U.S. jobs data, rising trade tensions, and renewed expectations of monetary easing.
Weak U.S. Jobs Data Shifts Sentiment
The latest U.S. labour market data revealed a significant slowdown in job creation, compounded by downward revisions to previous months. This undercut assumptions of resilience in the U.S. economy and ignited fears that growth is losing momentum. In response, markets are now pricing in two Federal Reserve rate cuts before year-end, with an estimated 100 to 140 basis points of easing through 2026. Expectations for a September cut have firmed, despite the Fed's neutral tone at last week's FOMC meeting.
Market reaction was swift: equities dropped, gold rallied, Treasury yields declined, and the U.S. dollar weakened. Safe-haven demand has increased, with gold regaining momentum after recent stagnation.
Tariff Shock Amplifies Economic Risks
The expiration of the August 1 trade deal deadline has added another layer of concern. Average U.S. import tariffs are now expected to rise to nearly 18%, after a series of partial deals failed to sufficiently lower the trade barriers. Notable developments include: 25% tariffs on India, in part as retaliation for Russian oil purchases.
35% tariffs on Canada, though mitigated by USMCA carve-outs.
A 15% base tariff on surplus-running countries and 10% on others.
These changes, effective from August 7, compound existing price pressures. Last week's PCE inflation data came in hotter than expected, suggesting that the inflationary pass-through from tariffs is beginning to materialize.
While the Fed's December projection of 3.1% core PCE inflation leaves some wiggle room, the elevated tariff burden could force a revaluation of both growth and inflation trajectories.
Earnings Season Solid, But Not Stellar
Although corporate earnings have been broadly robust, especially outside of Big Tech, they haven't been extraordinary. Markets had rallied on strong earnings and economic resilience but were arguably overextended. The sudden influx of negative data has exposed fragile sentiment.
Despite the downturn, Monday opened with a rebound attempt in global equities, suggesting ongoing dip-buying interest. European and Japanese indices, as well as U.S. futures, pointed higher, indicating that investors are still willing to take positions on pullbacks.
Adding to market nerves, President Trump reportedly dismissed the head of the Bureau of Labor Statistics, accusing her of politically motivated data manipulation. This introduces fresh political risk, particularly as tensions between the Trump administration and the Federal Reserve resurface.
Bank of England Preview: A Tough Balancing Act
Attention now shifts to the Bank of England (BoE), which meets this Thursday. A 25bps rate cut is widely expected, placing the BoE squarely between the ECB and the Fed in terms of policy stance.
The UK economy faces slow growth and sticky services inflation. Labour market weakness is starting to emerge, increasing the risk of stagflation. The vote split will be closely watched, especially for signs that some Monetary Policy Committee (MPC) members are pushing for a 50bps cut.
The BoE faces structural economic challenges that rate cuts may not fully address. A Bloomberg report noted that while deposit rates have dropped, the mortgage market structure has delayed relief for households. Savers are feeling the pinch, but borrowers have yet to benefit from lower rates.
Looking Ahead:
Markets remain fragile and reactive to headline risk. With limited U.S. data this week, focus will stay on: The application of new U.S. tariffs on August 7
Remaining corporate earnings reports
BoE policy messaging and vote split
Although the fundamental economic outlook remains uncertain, one thing is clear: investor sentiment is no longer unshakable. Traders will need to navigate a complex mix of macro risks, political drama, and central bank recalibrations as the second half of the year unfolds.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump Threatens to Raise Pharma Tariffs to 250%
Trump Threatens to Raise Pharma Tariffs to 250%

See - Sada Elbalad

timean hour ago

  • See - Sada Elbalad

Trump Threatens to Raise Pharma Tariffs to 250%

Taarek Refaat President Donald Trump told Squackbox on Tuesday that planned pharmaceutical tariffs imported into the United States could eventually reach 250%, the highest threat to date, according to CNBC. He added that he would initially impose "small tariffs" on medicines, then raise them to 150%, then to 250%, within a year or a year and a half maximum. The president has repeatedly threatened, then changed course on tariff proposals, so there is no guarantee that he will eventually set tariffs on drugs at 250%. In early July, Trump threatened to impose tariffs of 200% on drugs. In April, the Trump administration launched a so-called Article 232 investigation on pharmaceutical products, a legal authority that allows the Commerce Secretary to investigate the impact of imports on national security. The tariffs are an attempt by the president to motivate pharmaceutical companies to move manufacturing operations to the United States at a time when the manufacture of drugs locally has seen a sharp contraction over the past few decades. Over the past six months, companies such as Ellie Lily and Johnson & Johnson have announced new U.S. investments to strengthen their ties with the president. 'We want the pharmaceutical industry in our country,' Trump told CNBC. The planned tariffs will deal a major blow to the pharmaceutical industry, which has warned that tariffs could raise costs, hinder investments in the United States, and disrupt the drug supply chain, putting patients at risk. Pharmaceutical companies are already facing the repercussions of Trump's drug pricing policies, which they argue threaten their profits and their ability to invest in research and development. That includes Trump's executive order in May that revives a controversial plan, a 'most-preferred-country' policy, which aims to reduce drug costs by peging the prices of some drugs in the United States to prices much lower abroad. On Tuesday, Trump told CNBC that he "did" the "most-favoured nation" policy, and that this would have a "huge impact on drug prices." However, Trump has not officially implemented any changes to the executive order. Last week, Trump sent letters to 17 pharmaceutical companies calling on them to commit to taking steps to reduce the prices of US drugs by September 29. This includes agreeing to provide their entire range of existing drugs at the lowest price provided in other developed countries for each patient benefiting from the Medicaid program, among other steps, while some pharmaceutical companies have announced that they are reviewing messages. read more CBE: Deposits in Local Currency Hit EGP 5.25 Trillion Morocco Plans to Spend $1 Billion to Mitigate Drought Effect Gov't Approves Final Version of State Ownership Policy Document Egypt's Economy Expected to Grow 5% by the end of 2022/23- Minister Qatar Agrees to Supply Germany with LNG for 15 Years Business Oil Prices Descend amid Anticipation of Additional US Strategic Petroleum Reserves Business Suez Canal Records $704 Million, Historically Highest Monthly Revenue Business Egypt's Stock Exchange Earns EGP 4.9 Billion on Tuesday Business Wheat delivery season commences on April 15 News Israeli-Linked Hadassah Clinic in Moscow Treats Wounded Iranian IRGC Fighters Arts & Culture "Jurassic World Rebirth" Gets Streaming Date News China Launches Largest Ever Aircraft Carrier News Ayat Khaddoura's Final Video Captures Bombardment of Beit Lahia Business Egyptian Pound Undervalued by 30%, Says Goldman Sachs Videos & Features Tragedy Overshadows MC Alger Championship Celebration: One Fan Dead, 11 Injured After Stadium Fall Lifestyle Get to Know 2025 Eid Al Adha Prayer Times in Egypt Arts & Culture South Korean Actress Kang Seo-ha Dies at 31 after Cancer Battle Arts & Culture Lebanese Media: Fayrouz Collapses after Death of Ziad Rahbani Sports Get to Know 2025 WWE Evolution Results

Trump says incoming pharma tariff may go as high as 250% - Economy
Trump says incoming pharma tariff may go as high as 250% - Economy

Al-Ahram Weekly

timean hour ago

  • Al-Ahram Weekly

Trump says incoming pharma tariff may go as high as 250% - Economy

US President Donald Trump said Tuesday that upcoming tariffs on imported pharmaceuticals could reach 250 percent, after starting at a lower level, while adding he plans to also unveil fresh duties on foreign semiconductors. "We'll be putting (an) initially small tariff on pharmaceuticals, but in one year, one-and-a-half years, maximum, it's going to go to 150 percent," Trump said in an interview on CNBC. "And then it's going to go to 250 percent because we want pharmaceuticals made in our country," he added. In the same interview, Trump said he expects to raise the US tariff on Indian imports "very substantially over the next 24 hours" due to the country's purchases of Russian oil. While Trump has taken aim at products from different countries with varying tariff rates after imposing a 10-percent levy on almost all trading partners in April, these have excluded certain products he planned to target separately. These sector-specific tariffs have generally come after government investigations that look into the national security concerns surrounding certain imports. After earlier embarking on probes on imported semiconductors and pharmaceuticals, the Trump administration has signaled plans to wrap up these studies which could lead to new tariffs. Already, Trump has slapped steep tariffs of 50 percent on imported steel and aluminum, and also rolled out a separate but lower duty on autos and parts. Follow us on: Facebook Instagram Whatsapp Short link:

Israel to partially reopen Gaza private goods trade - War on Gaza
Israel to partially reopen Gaza private goods trade - War on Gaza

Al-Ahram Weekly

time8 hours ago

  • Al-Ahram Weekly

Israel to partially reopen Gaza private goods trade - War on Gaza

Israel will partially reopen private sector trade with Gaza to reduce its reliance on humanitarian aid, the defence ministry's civil affairs agency for the Palestinian territories said Tuesday. As part of the call mechanism, a limited number of Palestinian merchants were approved by the Israeli occupation authorities, subject to several criteria and strict security screening, COGAT said. Israel has been attacking Gaza for 22 months and imposed a total blockade on the Palestinian strip on March 2, partially lifted in May to allow a US-backed private agency to open food distribution centres. Aid convoys and airdrops by Arab and European militaries resumed last month, as UN-mandated expert reports warned famine was unfolding in the war-torn territory. The COGAT statement said local private sector deliveries would be paid for by monitored bank transfers and be subject to inspections by the Israeli army before entering Gaza, "to prevent the involvement of the Plastenian resistance groups" Permitted goods under the new mechanism will include food staples, fruits, vegetables, baby formula and hygiene products, COGAT said. * This story was edited by Ahram Online. Follow us on: Facebook Instagram Whatsapp Short link:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store